Male testosterone treatment for men can be challenging, especially for those who have had an untreated or low-grade case of prostate cancer.
But a new study from Johns Hopkins Medicine suggests that one of the most effective options is the combination of testosterone and a low-dose estrogen called progesterone.
In this case, the treatment can help men with the most common form of prostate and its symptoms, according to the study published in the journal Science Translational Medicine.
While most men can tolerate testosterone-only therapy, some have had success with the combination.
And the researchers who conducted the study hope to expand the study to men who have other risk factors for prostate cancer, such as having a family history of prostate or a diagnosis of testicular cancer.
“What we found is that there is a real need for this treatment for these men,” lead study author Dr. Andrew Wiebe, a professor of medicine at Johns Hopkins, told Reuters Health by phone.
“What we have found is there is no specific test that can predict which is the best way to treat prostate cancer.”
Read more about prostate cancer:What is prostate cancer?
Prostate cancer is the most aggressive form of cancer.
It can be fatal, but only about 20 percent of men with it die from the disease.
It’s also rare, affecting between 2.5 to 7 percent of the population.
It affects men in all stages of menopause, and it affects men of all races, ages and genders.
The disease is caused by abnormal cell division that results in the growth of abnormal tissue called tumors.
The growth of the tumor is caused mainly by an abnormally large amount of a protein called testosterone.
The prostate is located on the underside of the bladder and is the only part of the body that is not made of skin.
The treatment for prostate-specific antigen (PSA) antibodies, or T-cells, is to suppress the cells.
In contrast, testosterone blocks the production of T-cell-stimulating factor (T-GF), which signals the body to make antibodies to attack prostate cancer cells.
When the antibodies target the cancer, they destroy the cancer.
The new study involved testing the ability of two different testosterone treatments to treat the symptoms of prostate-cancer in patients with normal T- cells.
The first treatment was taken from the combination testosterone pill and the progesterol-only pill.
The second treatment was a combination of progesteroid and testosterone.
Both treatments reduced symptoms of pain, fatigue, and erectile dysfunction in men who had been treated with the progestin-only hormone.
The men in the first study were treated with testosterone-based therapy for 15 weeks, while those in the second study were not.
The treatment lasted four weeks.
In both groups, the participants’ testosterone levels were measured at the end of treatment.
The results showed that the progosteroid-based treatment reduced symptoms in the men who received the testosterone-free therapy, and the testosterone therapy reduced symptoms for those in both groups who received both treatments.
Both treatments also helped the men’s symptoms improve significantly.
In fact, the progerone-only treatment showed a significant increase in the number of symptoms compared to the progestaion-based testosterone treatment.
But the study didn’t look at how the testosterone and progesterones differed from each other.
It was unclear whether testosterone had any effect on the number or quality of symptoms in men with prostate cancer compared to those without the cancer and whether the treatment did anything to lessen symptoms.
Dr. Wieber and his team decided to look at the effect of testosterone on the symptoms after determining that the testosterone could help reduce pain and fatigue for those men who were being treated with progesteroids.
“We found that the combination was a really effective treatment for pain and for fatigue, because we can’t do it with progestins alone,” Wiebel said.
The researchers also noted that the therapy could help men who may not be experiencing symptoms of the disease to get better, or for them to start to have more sex.
“The combination of the testosterone with progestaions helped these men to have better quality of life,” Wiedbe said.
“They were able to be more active and have more sexual activity.”
Wiebe and his colleagues have been studying the use of testosterone-related therapies for men for a number of years, and their previous studies have shown that the drug can help with symptoms.
However, the new study was the first to examine the impact of the treatment on symptoms in patients who had received progesterols and not.
In addition to Dr. Wiedbem and his coauthors, the study was supported by the National Institutes of Health (grants U10 HD2414081, HD2416094, and HD2401606) and the National Institute on Aging (grant GM1233262).